Speakers: 

Jordan Mosquera, Pharmacy Intern, Geisinger Medical Center - has nothing to disclose. 

Emma Oley, Pharmacy Intern, Geisinger Medical Center - has nothing to disclose. 

Makenzie Psarakis, Pharmacy Intern, Geisinger Medical Center - has nothing to disclose. 

Moderator: 

Sarah F. Hale, PharmD., BCPPS; Director of Pharmacy, Geisinger Medical Center - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• • Describe the current guidelines at Geisinger for the treatment of Clostridioides difficile infection.
  • Compare the effectiveness of fidaxomicin versus vancomycin in preventing C. difficile recurrence.
  • Review the literature supporting current practice of Dual Antiplatelet Therapy (DAPT) following drug-eluding stent placement.
  • Examine the use of extended 9-month clopidogrel monotherapy verses DAPT for patients with Acute Coronary Syndromes at high ischemic and bleeding risk.
  • Describe the role of interleukin-4 and interleukin-13 in type II inflammation.
  • Discuss the utility of dupilumab in reducing the number of moderate or severe chronic obstructive pulmonary disease exacerbations.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD; Brain Simpkins, PharmD; Jessica Milheim, CPhT and Nichole Varela Gonzalez, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.